Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing, Pediatrics, Pot: 21st Century Cures Amendments

Executive Summary

Committee members didn’t even vote on any amendments besides the manager’s package, but proposals floated and withdrawn offer glimpse at potential fights to come.

You may also be interested in...



HHS Envisions Drug Price Arbitration For Part D

Approaches for HHS to become involved in drug price negotiations between Medicare Part D plan sponsors and manufacturers were outlined by HHS Assistant Secretary for Planning and Evaluation Richard Frank at a policy conference, although current law would need to be revised to allow it.

Priority Review Vouchers Could Be Used Frequently Next Year

FDA requests enough pediatric rare disease priority review voucher user fees to fund three redemptions in fiscal year 2016.

Priority Review Weirdness: Tropical Voucher Sells For More; Owner Says It’s Worth Less

Knight Therapeutics says a rare pediatric disease voucher is more valuable than its tropical disease voucher despite the sale price.

Related Content

Topics

UsernamePublicRestriction

Register

PS056894

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel